Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Adam Knott, Istvan Lang, Christelle Levy, Denise A. Yardley, Jose Bines, Richard D. Gelber, Martine Piccart, APHINITY Steering Comm, Vivianne Tjan - Heijnen, Jose Baselga

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)122-131
Number of pages10
JournalNew England Journal of Medicine
Volume377
Issue number2
DOIs
Publication statusPublished - 13 Jul 2017

Keywords

  • PLUS DOCETAXEL
  • CHEMOTHERAPY
  • EFFICACY

Cite this

von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., Knott, A., Lang, I., Levy, C., Yardley, D. A., Bines, J., Gelber, R. D., Piccart, M., APHINITY Steering Comm, Tjan - Heijnen, V., & Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine, 377(2), 122-131. https://doi.org/10.1056/NEJMoa1703643